These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 17620372

  • 1. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC.
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
    [Abstract] [Full Text] [Related]

  • 2. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
    Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Eliopoulos GM.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2223-5. PubMed ID: 17404001
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
    Boucher HW, Sakoulas G.
    Clin Infect Dis; 2007 Sep 01; 45(5):601-8. PubMed ID: 17682996
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK.
    J Clin Microbiol; 2006 Feb 01; 44(2):595-7. PubMed ID: 16455920
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG, Gao W, Ward PB, Howden BP.
    J Antimicrob Chemother; 2011 May 01; 66(5):1057-60. PubMed ID: 21393156
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD, Pawlak J, Johnson LB, Saravolatz LD, Husain N.
    Int J Antimicrob Agents; 2010 Nov 01; 36(5):478-80. PubMed ID: 20846830
    [No Abstract] [Full Text] [Related]

  • 12. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG, Sader HS, Jones RN.
    J Antimicrob Chemother; 2006 Aug 01; 58(2):481-3. PubMed ID: 16847029
    [No Abstract] [Full Text] [Related]

  • 13. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
    Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G.
    J Antimicrob Chemother; 2007 Jun 01; 59(6):1190-3. PubMed ID: 17434881
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
    Cui L, Tominaga E, Neoh HM, Hiramatsu K.
    Antimicrob Agents Chemother; 2006 Mar 01; 50(3):1079-82. PubMed ID: 16495273
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
    Mangili A, Bica I, Snydman DR, Hamer DH.
    Clin Infect Dis; 2005 Apr 01; 40(7):1058-60. PubMed ID: 15825002
    [Abstract] [Full Text] [Related]

  • 18. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.
    Kuo CC, Wu VC, Huang YT, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2009 Jan 01; 33(1):96-8. PubMed ID: 18790610
    [No Abstract] [Full Text] [Related]

  • 19. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia.
    Naimi TS, Anderson D, O'Boyle C, Boxrud DJ, Johnson SK, Tenover FC, Lynfield R.
    Clin Infect Dis; 2003 Jun 15; 36(12):1609-12. PubMed ID: 12802763
    [Abstract] [Full Text] [Related]

  • 20. Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.
    Gaupp R, Lei S, Reed JM, Peisker H, Boyle-Vavra S, Bayer AS, Bischoff M, Herrmann M, Daum RS, Powers R, Somerville GA.
    Antimicrob Agents Chemother; 2015 Jul 15; 59(7):4226-38. PubMed ID: 25963986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.